Rahul Gosain, MD

Treatment Practices for Extended-Stage Small Cell Lung Cancer

Eric Singhi, MD, joins the Oncology Brothers to discuss adverse event management practices for patients with small cell lung cancer.

Incorporating PCI Following ADRIATIC Study

Medical oncologists provide comprehensive insights on treatment practices for patients with extended-stage small cell lung cancer.

Treatment Algorithm for Limited-Stage Small Cell Lung Cancer

Following recent data from the ADRIATIC study, the Oncology Brothers and Eric Singhi, MD, discuss the role of prophylactic cranial irradiation (PCI) in patients with small cell lung cancer.

Adverse Effects Associated With JAK Inhibitors in Myelofibrosis

Eric Singhi, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the treatment algorithm for patients with limited-stage small cell lung cancer (SCLC), highlighting the ADRIATIC study.

Naveen Pemmaraju, MD, with the Oncology Brothers

Rahul Gosain, MD;Rohit Gosain, MD;Naveen Pemmaraju, MD

Managing Anemia and Splenomegaly in Myelofibrosis

Naveen Pemmaraju, MD, discusses adverse effects associated with JAK inhibitors in the treatment of myelofibrosis, and the Oncology Brothers recap the entire discussion.

Rahul Gosain, MD;Rohit Gosain, MD;Naveen Pemmaraju, MD

JAK Inhibitors in Myelofibrosis

An expert on myelofibrosis discusses anemia and splenomegaly management practices for patients with myelofibrosis.

Rahul Gosain, MD;Rohit Gosain, MD;Naveen Pemmaraju, MD

Supportive Care in Myelofibrosis

Naveen Pemmaraju, MD, gives a comprehensive overview of JAK inhibitors available for the treatment of patients with myelofibrosis.

Rahul Gosain, MD;Rohit Gosain, MD;Naveen Pemmaraju, MD

Patient Diagnostic Workup Practices

A hematology specialist provides clinical insights on supportive care practices for patients with myelofibrosis.

Rahul Gosain, MD;Rohit Gosain, MD;Naveen Pemmaraju, MD

Advice for Community Oncologists Treating R/R Multiple Myeloma

Naveen Pemmaraju, MD, joins Rohit Gosain, MD, and Rahul Gosain, MD, to discuss diagnostic practices and prognostic factors for patients with myelofibrosis.

Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD

Rahul Gosain, MD;Rohit Gosain, MD;Samer A. Al'Hadidi, MD

Treatment Decision-Making in Relapsed/Refractory Multiple Myeloma

Samer Al'Hadidi, MD, offers advice to community oncologists who treat patients with relapsed/refractory multiple myeloma, and the Oncology Brothers recap the entire discussion.

Rahul Gosain, MD;Rohit Gosain, MD;Samer A. Al'Hadidi, MD

Adverse Effect Management for CAR T-Cell Therapy and Bispecifics in R/R MM

Rohit Gosain, MD, and Rahul Gosain, MD, are joined by Samer Al'Hadidi, MD, to discuss treatment decision-making strategies for patients with relapsed/refractory multiple myeloma.

Rahul Gosain, MD;Rohit Gosain, MD;Samer A. Al'Hadidi, MD

The Role of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

In a discussion with the Oncology Brothers on the treatment of patients with relapsed/refractory multiple myeloma, Samer Al'Hadidi, MD, discusses adverse effects associated with CAR T-cell therapy and bispecific antibodies.

Rahul Gosain, MD;Rohit Gosain, MD;Samer A. Al'Hadidi, MD

Monitoring Patients with Relapsed/Refractory Multiple Myeloma

An expert on the treatment of multiple myeloma discusses the role of CAR T-cell therapy in relapsed/refractory disease.

Rahul Gosain, MD;Rohit Gosain, MD;Samer A. Al'Hadidi, MD

Adverse Effects Associated with SBRT in Patients With HCC

Samer Al'Hadidi, MD, discusses monitoring strategies for patients with relapsed/refractory multiple myeloma who are receiving lenalidomide.

Rahul Gosain, MD;Rohit Gosain, MD;Nina Sanford, MD;Jeffrey M. Ryckman, MD;Harris Chengazi, MD

Treating Transplant-Ineligible Patients With HCC and Liver-Confined Disease

The panel discusses adverse effects associated with stereotactic body radiation therapy, and the Oncology Brothers provide a recap of the entire discussion.

Rahul Gosain, MD;Rohit Gosain, MD;Nina Sanford, MD;Jeffrey M. Ryckman, MD;Harris Chengazi, MD

Overview of Interventional Radiology Treatment Options

Focusing on liver-directed therapy, the panel provides clinical insights on the treatment of patients with hepatocellular carcinoma who have liver-confined disease and are not candidates for transplant.

Rahul Gosain, MD;Rohit Gosain, MD;Nina Sanford, MD;Jeffrey M. Ryckman, MD;Harris Chengazi, MD

The Basics of Radiation Oncology

Providing the interventional radiologist perspective, Harris Chengazi, MD, gives an overview of available treatment strategies.

Rahul Gosain, MD;Rohit Gosain, MD;Nina Sanford, MD;Jeffrey M. Ryckman, MD;Harris Chengazi, MD

Key Takeaways on Optimizing Multiple Myeloma Care

Radiation oncologists Nina Sanford, MD, and Jeffrey M. Ryckman, MD, provide an overview of treatment modalities, highlighting SRS, SBRT, proton therapy, and how options have improved.

Caitlin Costello, MD, with the Oncology Brothers

Rahul Gosain, MD;Rohit Gosain, MD;Caitlin Costello, MD

Maintenance Therapy in Patients with Multiple Myeloma

Caitlin Costello, MD, offers concluding remarks and guidance to healthcare providers on optimizing multiple myeloma patient care.

Rahul Gosain, MD;Rohit Gosain, MD;Caitlin Costello, MD

Monitoring Induction Therapy & MRD in Multiple Myeloma

A medical expert shares her treatment approach for a high-risk multiple myeloma patient, considering transplant eligibility, dose escalations, and maintenance therapy based on induction regimen and patient risk factors.

Rahul Gosain, MD;Rohit Gosain, MD;Caitlin Costello, MD

Tailoring Treatment for Patients with Multiple Myeloma

Caitlin Costello, MD, shares insights on the role of minimal residual disease (MRD) assessment in the multiple myeloma treatment process, including its impact on induction therapy and disease monitoring.

Rahul Gosain, MD;Rohit Gosain, MD;Caitlin Costello, MD

The Role of Biomarkers in Diagnosing Multiple Myeloma

A medical expert discusses tailoring treatment strategies for standard-risk and high-risk multiple myeloma patients, considering patient characteristics and transplant eligibility when selecting treatment combinations.

Rahul Gosain, MD;Rohit Gosain, MD;Caitlin Costello, MD

Advancing CLL Treatment: Latest Updates and Strategies

Caitlin Costello, MD, explores the evolving role of biomarkers in the early diagnosis and treatment of multiple myeloma, highlighting their impact on the changing landscape of the disease.

Rahul Gosain, MD; Nitin Jain, MD; and Rohit Gosain, MD, presenting slides

Comparing BTK Inhibitors for Optimal CLL Treatment

Nitin Jain, MD, discusses a novel treatment approach for chronic lymphocytic leukemia, along with stem cell transplantation and other later-line therapies and treatment options for managing CLL.

Personalized Medicine: Optimizing Outcomes for Patients with CLL

Nitin Jain, MD, discusses the increasing use of various Bruton's tyrosine kinase inhibitors as front-line treatment options for patients with chronic lymphocytic leukemia.

Observation Versus Treatment for Patients with CLL

Nitin Jain, MD, presents data on the efficacy of various chronic lymphocytic leukemia treatments, reviews current guidelines, discusses the increasing use of Bruton's tyrosine kinase inhibitors and the decreasing role of chemotherapy in his practice. He emphasizes the importance of considering patient factors and preferences in treatment decision-making.